We are live on ! Find out more
ALXO icon

ALX Oncology

93 hedge funds and large institutions have $2.47B invested in ALX Oncology in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 47 increasing their positions, 17 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

340% more call options, than puts

Call options by funds: $3.96M | Put options by funds: $900K

176% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 17

33% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 12

4% more funds holding

Funds holding: 8993 (+4)

1.73% more ownership

Funds ownership: 81.78%83.51% (+1.7%)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

11% less capital invested

Capital invested by funds: $2.78B → $2.47B (-$311M)

Holders
93
Holders Change
+4
Holders Change %
+4.49%
% of All Funds
1.63%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
16
Increased
47
Reduced
17
Closed
12
Calls
$3.96M
Puts
$900K
Net Calls
+$3.06M
Net Calls Change
+$2.91M
Name Holding Trade Value Shares
Change
Change in
Stake
VP
1
venBio Partners
California
$715M
VC
2
Vivo Capital
California
$311M
LGM
3
Logos Global Management
California
$233M
Wellington Management Group
4
Wellington Management Group
Massachusetts
$196M +$53.4M +678,456 +34%
BlackRock
5
BlackRock
New York
$112M +$11.5M +145,731 +11%
Vanguard Group
6
Vanguard Group
Pennsylvania
$100M +$37.3M +473,846 +54%
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$97.5M -$20.2M -256,323 -16%
Fidelity Investments
8
Fidelity Investments
Massachusetts
$92.1M +$14.2M +181,009 +17%
RG
9
Redmile Group
California
$72.2M +$1.43M +18,200 +2%
State Street
10
State Street
Massachusetts
$68.4M +$42.9M +544,900 +142%
CAM
11
Cormorant Asset Management
Massachusetts
$65M
FCMI
12
Foresite Capital Management IV
California
$58M -$14.8M -187,569 -19%
AG
13
Artal Group
Luxembourg
$38.7M +$17.7M +225,000 +75%
BOTOTLSJU
14
Board of Trustees of The Leland Stanford Junior University
California
$38.3M -$73M -928,032 -64%
PAMU
15
Pictet Asset Management (UK)
United Kingdom
$31M -$556K -7,067 -2%
Ensign Peak Advisors
16
Ensign Peak Advisors
Utah
$24.8M +$24.3M +309,255 +1,144%
FCMV
17
Foresite Capital Management V
California
$23.6M
Geode Capital Management
18
Geode Capital Management
Massachusetts
$20.1M +$7.17M +91,149 +50%
Goldman Sachs
19
Goldman Sachs
New York
$18.7M +$9.58M +121,757 +93%
Franklin Resources
20
Franklin Resources
California
$14.7M
UBS AM
21
UBS AM
Illinois
$13.5M +$11.8M +149,651 +451%
Northern Trust
22
Northern Trust
Illinois
$13M +$4.41M +56,003 +47%
O
23
OrbiMed
New York
$11.1M
SFM
24
Sphera Funds Management
Israel
$9.61M -$244K -3,097 -2%
Axa
25
Axa
France
$6.98M +$899K +11,420 +14%

ALXO Hedge Fund Activity: Q1 2021 in Review

93 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2021, worth a combined $2.47B — down 11% from $2.78B a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ALXO positions and 12 closed out — a net gain of 4 holders — while 47 added to existing stakes and 17 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $53.4M. The largest seller was Board of Trustees of The Leland Stanford Junior University, cutting an estimated $73M.

  • 93 institutional investors held ALX Oncology (ALXO) as of Q1 2021, up from 89 in Q4 2020.
  • Funds reported $2.47B of ALX Oncology stock for Q1 2021, down 11% quarter-over-quarter.
  • 16 funds opened new ALX Oncology positions in Q1 2021 and 12 closed out, a net change of +4 holders.
  • The largest ALX Oncology buyer in Q1 2021 was Wellington Management Group, an estimated $53.4M added.
  • The largest ALX Oncology seller in Q1 2021 was Board of Trustees of The Leland Stanford Junior University, an estimated $73M sold.

Based on aggregated 13F filings for Q1 2021.